Investigational drug · Phase 3
JSKN033
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "JSKN033"
First trial start
2025
Jan 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JSKN033", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cervical Cancer
- Recurrent or Metastatic Cervical Cancer
- Advanced Malignant Tumors
- Non Small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JSKN033" as an intervention, largest first.
- JSKN033 in Chinese Subjects with Advanced Malignant TumorsNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06770881 · 430 participants (planned) · Start Jan 15, 2025 · Primary completion Dec 31, 2026
Drug: JSKN033 · For: Advanced Malignant Tumors
- JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical CancerPivotal-lookingNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07797153 · 368 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: JSKN033; Docetaxel and 3 more · For: Recurrent or Metastatic Cervical Cancer
Sites: Guangzhou, China; Shanghai, China
- A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07283198 · 160 participants (planned) · Start Dec 10, 2025 · Primary completion Aug 30, 2027
Drug: JSKN033 Injection · For: Non Small Cell Lung Cancer (NSCLC)
- JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerNot yet recruiting
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT07497074 · 78 participants (planned) · Start Apr 2026 · Primary completion Oct 2027
Drug: JSKN033; Platinum and 1 more · For: Cervical Cancer
Sites: Guangzhou, China; Hangzhou, China
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06226766 · 11 participants · Start Jan 18, 2024 · Primary completion Jul 31, 2025
Drug: JSKN033 Injection · For: Advanced Solid Tumor
Sites: Randwick, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Subcutaneous administration of antibody-drug conjugates: current challenges, emerging opportunities, and future perspectives.
Ren S, Wang SS, Li FY · Antib Ther 2026
- Adverse events induced by the subcutaneous HER2-targeted antibody-drug conjugate JSKN033 in a male patient with breast cancer: A case report.
Yang R, Zhang J, Wang Y · Oncol Lett 2026
Also in development for Cervical Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- BAT1308Recombinant humanized anti-PD-1 monoclonal antibodyPhase 32 trials
Bio-Thera Solutions · Cervical Cancer, Advanced Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.